TNYA

Tenaya Therapeutics, Inc. (TNYA) | Rumor.io

Tenaya Therapeutics

TNYA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,042

Bullish sentiment (50-day avg)80%

Price to earnings ratio-0.99

Market capitalization132.3M

Earnings per share-0.51

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-90.6M

Social

What share of all stock conversation is about TNYA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0% +0	0% +0	0% 0

Sep 28

The heavy selling in TNYA may be easing, with the low holding on the retest and a stronger rebound following, supporting possible seller exhaustion.
The close of TNYA was mixed, with the low holding but the late rally fading, and reported volume at 4:01 p.m. supporting "heavy turnover and stabilization."
TNYA's TN-401 is expected to have a pivotal/FDA pathway update by year-end, with the only firm guidance being Q4 2026.

Generated by AI

Sentiment

Of the messages about TNYA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +13.04	66.67% -16.88	76.09% -15.07	83.28% -0.87
Bearish	0% -13.04	33.33% +16.88	23.91% +15.07	16.72% +0.87

Bullish· Jun 3

Tenaya Therapeutics, Inc. has cleared its biggest scientific hurdle by proving 100% efficacy in reducing cardiac hypertrophy across evaluable patients and gaining elite regulatory pathways (EMA PRIME and FDA RDEP).
The company's data is great, and many investors believe that the stock price will follow, with some expecting a significant increase in the coming weeks and months.
The clinical trial results are "absolutely stellar" and "life-changing" for patients, and many believe that the stock will not be a sub one dollar stock for very long.

Bearish· Jun 3

$TNYA is expected to experience a short squeeze, with the potential for a price spike after being pushed down for months.
The company's recent results, including positive data on its treatments, have been met with a lack of market response, suggesting that the market may be overly bearish.
The stock's price may be artificially depressed due to short selling, with some users suggesting that the market would be more favorable if shorting were outlawed.

Generated by AI

Topics

Of the messages about TNYA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	5%	32.24%	19.08%
Technical Analysis	100%	95%	65.42%	40.95%
Analysts	0%	0%	2.34%	26.04%
Controversies	0%	0%	0%	0.31%
Macro	0%	0%	0%	13.02%
Earnings	0%	0%	0%	0.59%

Announcements· Mar 5

Tenaya Therapeutics has entered into a research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics.
The collaboration involves an upfront payment of up to $10 million to Tenaya, as well as potential milestone payments of up to $1.13 billion.
Tenaya is eligible to receive up to $1.13 billion in total development, regulatory, and commercial milestone payments, plus royalties on any approved products, if successful targets advance.

Technical Analysis· Dec 10

A potential breakout is predicted for $TNYA, indicating a possible increase in price.
The breakout could be significant, but no specific price target or timing is mentioned.
This post focuses on technical analysis, suggesting a chart-based evaluation of the asset's price movement.

Generated by AI

Community

Of the messages about TNYA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	81.21%	86.12%	61.6%
Newcomers	33.33%	18.79%	13.88%	38.4%

Regulars· Sep 24

The company's fundamental story and long-term potential are more important than short-term price action, and the author is holding their position as long as there is no major deterioration in the clinical development of TN-201 and TN-401, the regulatory process, or the company's fundamental story.
The author believes that hitting the level of $0.62 once and for all could lead to a rebound, and they have no concerns about the stock's medium-term prospects.
The author is bearish on the stock and expects radio silence from the company for 1-2 months before they release any updates, and they believe that the company's lack of transparency and failure to update retail investors will lead to further price drops.

Newcomers· Mar 5

Tenaya Therapeutics, Inc. has partnered with Alnylam in a $1.13 billion deal to develop treatments for cardiovascular disease, with the company set to validate up to 15 gene targets.
The partnership has led to a surge in Tenaya Therapeutics' stock price, with shares increasing by 27.98% on high volume trading.
The collaboration has significant potential value, with milestone payments reaching up to $1.14 billion, and has been hailed as a major deal that could lead to prices previously unseen.

Generated by AI

RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease,

16d agoYahoo Finance

Tenaya at H.C. Wainwright conference: gene therapy data build

19d agoInvesting.com

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will host investor meetings at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026 and the Morgan Stanley 24th Annual Global Healthcare

27d agoYahoo Finance

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two...

1mo agoBarchart.com

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics (NASDAQ:TNYA) expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion. Hyllengren, who said he had be

1mo agoYahoo Finance

Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock

1mo agoInvesting.com

Also Discussed

Investors talking about TNYA also mention

#	Name	Attention
1	INZY - Inozyme Pharma, Inc.	——
2	Cullinan Therapeutics Inc.CGEM	0%new
3	ALX Oncology Holdings Inc.ALXO	0%0
4	Fate Therapeutics Inc.FATE	0%0
5	Prelude Therapeutics IncorporatedPRLD	0%0
6	Cabaletta Bio Inc.CABA	0%0
7	Lexeo Therapeutics, Inc. Common StockLXEO	0%+0
8	XTI Aerospace, Inc.XTIA	0%+0
9	Alnylam Pharmaceuticals, Inc.ALNY	0%0
10	TERN - Terns Pharmaceuticals, Inc.	——

Tenaya Therapeutics, Inc.

Healthcare
Biotechnology

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for heart disease. The company’s current pipeline centers on gene therapy programs such as TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, along with TN-301, a small molecule HDAC6 inhibitor being studied for heart failure with preserved ejection fraction. Tenaya Therapeutics also works through integrated platforms in gene therapy, cellular regeneration, and precision medicine to address the underlying drivers of inherited and other cardiovascular conditions. Headquartered in South San Francisco, California, the company serves the healthcare and biotechnology markets through research, discovery, and clinical development of cardiovascular treatments.

Website

Location

171 Oyster Point Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about TNYA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0% +0	0% +0	0% 0

Sep 28

The heavy selling in TNYA may be easing, with the low holding on the retest and a stronger rebound following, supporting possible seller exhaustion.
The close of TNYA was mixed, with the low holding but the late rally fading, and reported volume at 4:01 p.m. supporting "heavy turnover and stabilization."
TNYA's TN-401 is expected to have a pivotal/FDA pathway update by year-end, with the only firm guidance being Q4 2026.

Generated by AI

Sentiment

Of the messages about TNYA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +13.04	66.67% -16.88	76.09% -15.07	83.28% -0.87
Bearish	0% -13.04	33.33% +16.88	23.91% +15.07	16.72% +0.87

Bullish· Jun 3

Tenaya Therapeutics, Inc. has cleared its biggest scientific hurdle by proving 100% efficacy in reducing cardiac hypertrophy across evaluable patients and gaining elite regulatory pathways (EMA PRIME and FDA RDEP).
The company's data is great, and many investors believe that the stock price will follow, with some expecting a significant increase in the coming weeks and months.
The clinical trial results are "absolutely stellar" and "life-changing" for patients, and many believe that the stock will not be a sub one dollar stock for very long.

Bearish· Jun 3

$TNYA is expected to experience a short squeeze, with the potential for a price spike after being pushed down for months.
The company's recent results, including positive data on its treatments, have been met with a lack of market response, suggesting that the market may be overly bearish.
The stock's price may be artificially depressed due to short selling, with some users suggesting that the market would be more favorable if shorting were outlawed.

Generated by AI

Topics

Of the messages about TNYA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	5%	32.24%	19.08%
Technical Analysis	100%	95%	65.42%	40.95%
Analysts	0%	0%	2.34%	26.04%
Controversies	0%	0%	0%	0.31%
Macro	0%	0%	0%	13.02%
Earnings	0%	0%	0%	0.59%

Announcements· Mar 5

Tenaya Therapeutics has entered into a research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics.
The collaboration involves an upfront payment of up to $10 million to Tenaya, as well as potential milestone payments of up to $1.13 billion.
Tenaya is eligible to receive up to $1.13 billion in total development, regulatory, and commercial milestone payments, plus royalties on any approved products, if successful targets advance.

Technical Analysis· Dec 10

A potential breakout is predicted for $TNYA, indicating a possible increase in price.
The breakout could be significant, but no specific price target or timing is mentioned.
This post focuses on technical analysis, suggesting a chart-based evaluation of the asset's price movement.

Generated by AI

Community

Of the messages about TNYA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	81.21%	86.12%	61.6%
Newcomers	33.33%	18.79%	13.88%	38.4%

Regulars· Sep 24

The company's fundamental story and long-term potential are more important than short-term price action, and the author is holding their position as long as there is no major deterioration in the clinical development of TN-201 and TN-401, the regulatory process, or the company's fundamental story.
The author believes that hitting the level of $0.62 once and for all could lead to a rebound, and they have no concerns about the stock's medium-term prospects.
The author is bearish on the stock and expects radio silence from the company for 1-2 months before they release any updates, and they believe that the company's lack of transparency and failure to update retail investors will lead to further price drops.

Newcomers· Mar 5

Tenaya Therapeutics, Inc. has partnered with Alnylam in a $1.13 billion deal to develop treatments for cardiovascular disease, with the company set to validate up to 15 gene targets.
The partnership has led to a surge in Tenaya Therapeutics' stock price, with shares increasing by 27.98% on high volume trading.
The collaboration has significant potential value, with milestone payments reaching up to $1.14 billion, and has been hailed as a major deal that could lead to prices previously unseen.

Generated by AI

Tenaya Therapeutics

Social

Sep 28

Bullish· Jun 3

Bearish· Jun 3

Announcements· Mar 5

Technical Analysis· Dec 10

Regulars· Sep 24

Newcomers· Mar 5

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya at H.C. Wainwright conference: gene therapy data build

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock

Also Discussed

Tenaya Therapeutics, Inc.

Company Information

Location

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya at H.C. Wainwright conference: gene therapy data build

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock

Also Discussed

Social

Sep 28

Bullish· Jun 3

Bearish· Jun 3

Announcements· Mar 5

Technical Analysis· Dec 10

Regulars· Sep 24

Newcomers· Mar 5